GS 5801

Drug Profile

GS 5801

Alternative Names: GS-5801

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 06 Oct 2016 Preclinical trials in Hepatitis B in USA (PO) before October 2016 (ACTRN12616001375448p)
  • 06 Oct 2016 Gilead Sciences plans a phase I trial for (chronic) Hepatitis B in USA and New Zealand (ACTRN12616001375448p)
  • 23 Sep 2016 Preclinical trials in Hepatitis B in New Zealand (PO) (ACTRN12616001260415p) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top